Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in B-cell Precursor ALL with High ABCB1 Expression
NCT03118128Completed
- Sponsor
- Hospital General de México "Dr. Eduardo Liceaga"
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of liquid metformin (Aspargo Labs) in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Hospital General de México "Dr. Eduardo Liceaga". Primary endpoints: Treatment Refractoriness at 28 days, Relapse Rate at 12 months and 1 more. Started Jan 2015; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03118128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118128.